Ken Griffin I Teos Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$10.09 - $17.97 $82,738 - $147,354	8,200 Added 34.31%	32,100 $327,000
Q2 2024 Aug 14, 2024	BUY	$10.33 - $18.09 $111,564 - $195,372	10,800 Added 82.44%	23,900 $354,000
Q1 2024 May 15, 2024	BUY	$9.89 - $13.64 $108,790 - $150,040	11,000 Added 523.81%	13,100 $178,000
Q4 2023 Feb 14, 2024	SELL	$8.57 - $11.06 $152,546 - $196,868	-17,800 Reduced 89.45%	2,100 $22,000
Q3 2023 Nov 14, 2023	BUY	$10.95 - $14.6 $192,720 - $256,960	17,600 Added 765.22%	19,900 $217,000
Q2 2023 Aug 14, 2023	BUY	$12.93 - $18.05 $25,860 - $36,100	2,000 Added 666.67%	2,300 $30,000
Q1 2023 May 15, 2023	SELL	$13.02 - $22.62 $20,832 - $36,192	-1,600 Reduced 84.21%	300 $4,000
Q4 2022 Feb 14, 2023	SELL	$17.77 - $21.6 $145,714 - $177,120	-8,200 Reduced 81.19%	1,900 $37,000
Q3 2022 Nov 14, 2022	SELL	$18.6 - $27.25 $282,720 - $414,200	-15,200 Reduced 60.08%	10,100 $192,000

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $304M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.